Advanced search
Publication Cover
mAbs Volume 16, 2024 - Issue 1
Submit an article Journal homepage
1,342
Views
0
CrossRef citations to date
0
Altmetric
Meeting Report

Proceedings of the 14th European immunogenicity platform open symposium on immunogenicity of biopharmaceuticals

Sophie Tourdota Pharmacokinetics, Dynamics and Metabolism, Pfizer Inc, Andover, MA, USACorrespondence[email protected]
View further author information
,
Daniel Baltrunkonisb Research and Development, Clinical Pharmacology and Bioanalytics, Clinical Bioanalytics, Groton, CT, USAView further author information
,
Sofie Deniesc SD Analytics, Bellem, BelgiumView further author information
,
Viswanath Devanarayand Eisai Inc, Nutley, NJ, USAView further author information
,
Joanna Grudzinska-Goebele DMPK Project Management, Pharmaceuticals R&D, Bayer AG, Berlin, GermanyView further author information
,
Arno Krommingaf BioNTech SE, Mainz, GermanyView further author information
,
Gregor P. Lotzg Roche Pharma Research and Early Development (pRED), Roche Innovation Center Munich, Hoffmann-La Roche Ltd, Penzberg, GermanyView further author information
,
Laurent Malherbeh Lilly Research Laboratories, a Division of Eli Lilly and Company, Indianapolis, IN, USAView further author information
,
Lydia Michauti Novartis Biomedical research, PK Sciences, Basel, SwitzerlandView further author information
,
Karin N. Weldinghj Department of Clinical Immunogenicity Analysis, Novo Nordisk A/S, Maaloev, DenmarkView further author information
,
Joao A. Pedras-Vasconcelosk Division of Biotech Review and Research III, Office of Biotechnology Products, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USAView further author information
,
Laura. I. Salazar-Fontanal LAIZ Regulatory Science, Lausanne, SwitzerlandView further author information
,
Sebastian Spindeldreherm Integrated Biologix GmbH, Basel, SwitzerlandView further author information
,
Zuben Saunan Division of hemostasis, Office of Plasma Protein Therapeutics; Office of Therapeutic Products, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USAView further author information
,
Veerle Snoecko Translational Biomarkers and Bioanalysis, UCB Biopharma SRL, Braine-l’Alleud, BelgiumView further author information
,
Daniela Verthelyip Division of Biologics Research and Review III; Ofrfice of Biotechnology Products; Center for Drug Evaluation and Research; Office of Pharmaceutical Quality, US Food and Drug Administration, Silver Spring, MD, USAView further author information
&
Daniel Kramerq Global Scientific Advisor Immunogenicity, Translational Medicine & Early Development, Sanofi Aventis Deutschland GmbH, Frankfurt am Main, GermanyView further author information
 show all
Article: 2324801 | Received 30 Jan 2024, Accepted 13 Feb 2024, Published online: 05 Mar 2024

References

  • Starcevic Manning M, Hassanein M, Partridge MA, Jawa V, Mora J, Ryman J, Barker B, Braithwaite C, Carleton K, Hay L. et al. Comparison of titer and signal to noise (S/N) for determination of anti-drug antibody magnitude using clinical data from an industry consortium. AAPS J. 2022;24(4):81. doi:10.1208/s12248-022-00728-8.
  • McCush F, Wang E, Yunis C, Schwartz P, Baltrukonis D. Anti-drug Antibody Magnitude and Clinical Relevance Using Signal to Noise (S/N): Bococizumab Case Study. AAPS J. 2023;25(5):85. doi:10.1208/s12248-023-00846-x.
  • FDA. 2022. Immunogenicity information in human prescription therapeutic protein and select drug product labeling — content and format. Guidance for Industry - draft guidance.
  • Ducret A, Ackaert C, Bessa J, Bunce C, Hickling T, Jawa V, Kroenke MA, Lamberth K, Manin A, Penny HL. et al. Assay format diversity in pre-clinical immunogenicity risk assessment: toward a possible harmonization of antigenicity assays. Mabs-austin. 2022;14(1):1993522. doi:10.1080/19420862.2021.1993522.
  • Karle AC, Wrobel MB, Koepke S, Gutknecht M, Gottlieb S, Christen B, Rubic-Schneider T, Pruimboom-Brees I, Leber XC, Scharenberg M. et al. Anti-brolucizumab immune response as one prerequisite for rare retinal vasculitis/retinal vascular occlusion adverse events. Sci Transl Med. 2023;15(681):eabq5241. doi:10.1126/scitranslmed.abq5241.
  • FDA. 2021. ANDAs for Certain Highly Purified Synthetic Peptide Drug Products That Refer to Listed Drugs of rDNA Origin for Certain Highly Purified Synthetic Peptide Drug Products That Refer to Listed Drugs of rDNA Origin
  • FDA. 2014. Immunogenicity Assessment for Therapeutic Protein Products - Guidance for Industry.
  • Simhadri VL, McGill J, McMahon S, Wang J, Jiang H, Sauna ZE. Prevalence of pre-existing antibodies to CRISPR-Associated nuclease Cas9 in the USA population. Mol Ther Methods Clin Dev. 2018;10:105–7. doi:10.1016/j.omtm.2018.06.006.
  • Charlesworth CT, Deshpande PS, Dever DP, Camarena J, Lemgart VT, Cromer MK, Vakulskas CA, Collingwood MA, Zhang L, Bode NM. et al. Identification of preexisting adaptive immunity to Cas9 proteins in humans. Nat Med. 2019;25(2):249–54. doi:10.1038/s41591-018-0326-x.
  • Wagner DL, Amini L, Wendering DJ, Burkhardt LM, Akyuz L, Reinke P, Volk HD, Schmueck-Henneresse M. High prevalence of Streptococcus pyogenes Cas9-reactive T cells within the adult human population. Nat Med. 2019;25(2):242–8. doi:10.1038/s41591-018-0204-6.
  • Simhadri VL, Hopkins L, McGill JR, Duke BR, Mukherjee S, Zhang K, Sauna ZE. Cas9-derived peptides presented by MHC class II that elicit proliferation of CD4(+) T-cells. Nat Commun. 2021;12(1):5090. doi:10.1038/s41467-021-25414-9.
  • Liu J, Liu Y, Xia H, Zou J, Weaver SC, Swanson KA, Cai H, Cutler M, Cooper D, Muik A. et al. BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants. Nature. 2021;596(7871):273–5. doi:10.1038/s41586-021-03693-y.
  • Sahin U, Kariko K, Tureci O. mRNA-based therapeutics — developing a new class of drugs. Nat Rev Drug Discov. 2014;13(10):759–80. doi:10.1038/nrd4278.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.